Pasithea Therapeutics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KTTA research report →
Range $3 – $3
Price Chart
About the company
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment.
- CEO
- Tiago Reis Marques
- IPO
- 2021
- Employees
- 5
- HQ
- Miami Beach, FL, US
Get TickerSpark's AI analysis on KTTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.85M
- P/E
- -0.19
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.07
- EV/EBITDA
- 1958.98
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -49.49%
- ROIC
- -48.04%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-20,857,295
- Net Income
- $-20,427,683-46.9%
- EPS
- $-2.91+77.1%
- OCF Growth
- -9.3%
- FCF Growth
- -9.3%
- 52W High
- $2.06
- 52W Low
- $0.28
- 50D MA
- $0.51
- 200D MA
- $0.69
- Beta
- 0.29
- RSI (14)
- 46
- Avg Volume
- 234.51K
No earnings-call transcripts are available for KTTA yet.
- Free Float
- 91.5%
- Shares Outstanding
- 33.41M
- Float Shares
- 30.58M
of shares held by institutions
21 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cable Car Capital LLC | 3.00M | ▲ 1.79M |
| Stonepine Capital Management, LLC | 2.20M | ▲ 1.37M |
| Adage Capital Partners Gp, L.L.C. | 2.10M | 0 |
| Jupiter Topco LLC | 2.10M | ▲ 2.10M |
| Janus Henderson Group Ltd. | 2.10M | 0 |
| Opaleye Management Inc. | 2.05M | ▲ 2.05M |
| Ameriprise Financial Inc | 1.86M | ▲ 513.59K |
| Squadron Capital Management LLC | 1.00M | ▼ 1.10M |
| Advisorshares Investments LLC | 937.55K | ▲ 600.04K |
| Vivo Capital, LLC | 465.47K | ▼ 1.63M |
| Persistent Asset Partners Ltd | 290.56K | 0 |
| Ubs Group AG | 188.11K | ▲ 161.96K |
Held by 7 ETFs
Biggest fund positions in KTTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Coastlands Capital LP | buy | 100,000 |
| May 1, 26 | Marques Tiago | other | 1,756,069 |
| May 1, 26 | STEINMAN LAWRENCE | other | 152,783 |
| May 1, 26 | Dumesnil Simon | other | 152,783 |
| May 1, 26 | Schneiderman Daniel H | other | 1,129,323 |
| May 1, 26 | Krishnan Kartik | other | 1,129,323 |
| May 1, 26 | Leahy Emer | other | 152,783 |
| May 1, 26 | Novak Alfred J | other | 152,783 |
| May 1, 26 | Krishnan Kartik | other | 0 |
| Apr 9, 26 | Coastlands Capital LP | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KTTA coverage
Recent articles, reports, and earnings notes.
No research on KTTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KTTA report →Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% – Time to Sell?
defenseworld.net · Oct 4
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
globenewswire.com · Sep 14
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
globenewswire.com · Sep 3
Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)
defenseworld.net · Aug 12
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
globenewswire.com · Jul 21
New Strong Buy Stocks for July 20th
zacks.com · Jul 20
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
globenewswire.com · Jul 8
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
globenewswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.